Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Merck & Company (DE:6MK)
XETRA:6MK
Merck & Company (6MK) Stock Price & Analysis
52 Followers
6MK Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€89.77 - €124.40
Previous Close€123
Volume4.00
Average Volume (3M)982.00
Market Cap
€310.47B
Enterprise Value€336.63B
Total Cash (Recent Filing)$7.09B
Total Debt (Recent Filing)$35.05B
Price to Earnings (P/E)149.0
Beta<0.01
Next Earnings
Jul 30, 2024EPS Estimate
€1.99Last Dividend Ex-Date
Mar 14, 2024Dividend Yield2.29%
Share Statistics
EPS (TTM)0.82
Shares Outstanding2,532,643,872
10 Day Avg. Volume651
30 Day Avg. Volume982
Standard Deviation0.06
R-Squared0.04
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)-203.48
Price to Sales (P/S)5.18
Price to Cash Flow (P/CF)336.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.60
Enterprise Value/Gross Profit7.65
Enterprise Value/Ebitda66.18
Forecast
1Y Price Target
€128.44Price Target Upside6.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering20
Merck & Company News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceMerck raised topline guidance to $63.1-64.3 billion and non-GAAP EPS to $8.53-8.65, reflecting strong financial performance and confidence in continued growth.
Product PerformanceKeytruda's growth surpasses expectations, reinforcing its robust sales and strong market position, while Lagevrio's sales more than doubled Street expectations, highlighting significant upside potential.
Research And DevelopmentWith recent approvals and a focus on diversification, Merck's investment in internal R&D and strategic partnerships promises expansion in multiple therapeutic areas, including oncology and cardiovascular health.
Bears Say
Drug PerformanceBridion could miss slightly, with US strength offset by ex-US erosion and greater erosion anticipated due to Japan LOE starting.
Financial PerformanceThere was a $779M asset impairment for gefapixant, following FDA's CRL.
Financial PerformanceOpEx could weigh on sales beat with the Street potentially underestimating the operational expenses.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.16% Insiders
21.73% Mutual Funds
20.94% Other Institutional Investors
57.17% Public Companies and
Individual Investors
6MK FAQ
What was Merck & Company’s price range in the past 12 months?
Merck & Company lowest stock price was €89.77 and its highest was €124.40 in the past 12 months.
What is Merck & Company’s market cap?
Currently, no data Available
When is Merck & Company’s upcoming earnings report date?
Merck & Company’s upcoming earnings report date is Jul 30, 2024 which is in 93 days.
How were Merck & Company’s earnings last quarter?
Merck & Company released its earnings results on Apr 25, 2024. The company reported €1.934 earnings per share for the quarter, beating the consensus estimate of €1.762 by €0.172.
Is Merck & Company overvalued?
According to Wall Street analysts Merck & Company’s price is currently Undervalued.
Does Merck & Company pay dividends?
Merck & Company pays a Quarterly dividend of €0.72 which represents an annual dividend yield of 2.29%. See more information on Merck & Company dividends here
What is Merck & Company’s EPS estimate?
Merck & Company’s EPS estimate is €1.99.
How many shares outstanding does Merck & Company have?
Merck & Company has 2,532,643,800 shares outstanding.
What happened to Merck & Company’s price movement after its last earnings report?
Merck & Company reported an EPS of €1.934 in its last earnings report, beating expectations of €1.762. Following the earnings report the stock price went up 1.515%.
Which hedge fund is a major shareholder of Merck & Company?
Among the largest hedge funds holding Merck & Company’s share is Fisher Asset Management LLC. It holds Merck & Company’s shares valued at 1B.
---
Merck & Company Stock Smart Score
Company Description
Merck & Company
Merck & Co., Inc. develops pharmaceutical and vaccine products. It also offers healthcare solutions and vaccines addressing animal health. The company was founded in 1891 and is headquartered in Kenilworth, NJ.
---
6MK Company Deck
---
6MK Earnings Call
Q1 2024
0:00 / 0:00
---
6MK Sales Breakdown
45.91% Oncology
22.09% Vaccines
5.64% Hospital Acute Care
5.60% Diabetes
20.75% Other
---
6MK Stock 12 Months Forecast
Average Price Target
€128.44
▲(6.50% Upside)
Technical Analysis
Merck & Company
―
Pfizer
―
Johnson & Johnson
―
Bristol-Myers Squibb
―
GlaxoSmithKline
―
Best Analysts Covering 6MK
1 Year
1 Year Success Rate
19/20 ratings generated profit
1 Year Average Return
+17.50%
reiterated a buy rating 3 days ago
Copying Geoff Meacham's trades and holding each position for 1 Year would result in 95.00% of your transactions generating a profit, with an average return of +17.50% per trade.
---